Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004193611 | SCV003699158 | uncertain significance | not specified | 2022-08-30 | criteria provided, single submitter | clinical testing | The c.865A>C (p.K289Q) alteration is located in exon 2 (coding exon 1) of the PIGC gene. This alteration results from a A to C substitution at nucleotide position 865, causing the lysine (K) at amino acid position 289 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003111737 | SCV003785964 | uncertain significance | not provided | 2022-05-12 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with PIGC-related conditions. This variant is present in population databases (rs777363797, gnomAD 0.02%). This sequence change replaces lysine, which is basic and polar, with glutamine, which is neutral and polar, at codon 289 of the PIGC protein (p.Lys289Gln). |